HDT Bio Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Employees
  • 55

Employees

  • Latest Deal Type
  • Grant

  • Latest Deal Amount
  • $1M

  • Investors
  • 7

HDT Bio General Information

Description

Operator of a clinical-stage company intended to develop ribonucleic-based vaccines and therapeutics for infectious disease and oncology. The company's formulation technology specializes in stabilizing and delivering nucleic acids via multiple routes of administration with enhanced thermostability and lyophilization product lines, including self-amplifying Ribonucleic vaccines and innate immune agonist therapeutics, enabling healthcare systems to address the critical unmet needs in treating cancers and infectious diseases across the globe.

Contact Information

Website
www.hdt.bio
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 1150 Eastlake Avenue East
  • Suite 200A
  • Seattle, WA 98109
  • United States
+1 (206)
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Pharmaceuticals
Vertical(s)
Corporate Office
  • 1150 Eastlake Avenue East
  • Suite 200A
  • Seattle, WA 98109
  • United States
+1 (206)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

HDT Bio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Grant 04-Oct-2023 $1M Completed Clinical Trials - Phase 1
7. Early Stage VC (Series A) 13-Jun-2022 Cancelled Clinical Trials - Phase 1
6. Seed Round 13-Oct-2022 Completed Clinical Trials - Phase 1
5. Grant 10-May-2022 Completed Clinical Trials - Phase 1
4. Grant 22-Apr-2022 Completed Clinical Trials - Phase 1
3. Seed Round 05-Oct-2020 Completed Pre-Clinical Trials
2. Grant 01-Sep-2020 $8.2M Completed Pre-Clinical Trials
1. Grant 01-Jan-2019 $1.05M Completed Startup
To view HDT Bio’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

HDT Bio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a clinical-stage company intended to develop ribonucleic-based vaccines and therapeutics for infectious dise
Biotechnology
Seattle, WA
55 As of 2026

Cambridge, MA
 

Mainz, Germany
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

HDT Bio Competitors (3)

One of HDT Bio’s 3 competitors is Moderna, a Formerly VC-backed company based in Cambridge, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Moderna Formerly VC-backed Cambridge, MA
BioNTech Formerly VC-backed Mainz, Germany
Arcturus Therapeutics Holdings Formerly VC-backed San Diego, CA
You’re viewing 3 of 3 competitors. Get the full list »

HDT Bio Patents

HDT Bio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026221982-A2 Nanoparticle and non-coding rna compositions Pending 14-Apr-2025
WO-2025184356-A1 Vaccines and compositions against gamma herpesviruses Pending 28-Feb-2024
EP-4791437-A1 Junction opener protein and nanoparticle compositions and uses thereof Pending 12-Oct-2023
WO-2025081013-A1 Junction opener protein and nanoparticle compositions and uses thereof Inactive 12-Oct-2023
AU-2024206838-A1 Nanoparticle complexes for enhanced safety Pending 06-Jan-2023 A61K39/12
To view HDT Bio’s complete patent history, request access »

HDT Bio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

HDT Bio Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
BARDA Government
Johnson & Johnson Innovation - JLABS Accelerator/Incubator
National Institutes of Health Government Minority
Angel (individual) Minority
Angel (individual) Minority
You’re viewing 5 of 7 investors. Get the full list »

HDT Bio FAQs

  • When was HDT Bio founded?

    HDT Bio was founded in 2018.

  • Where is HDT Bio headquartered?

    HDT Bio is headquartered in Seattle, WA.

  • What is the size of HDT Bio?

    HDT Bio has 55 total employees.

  • What industry is HDT Bio in?

    HDT Bio’s primary industry is Biotechnology.

  • Is HDT Bio a private or public company?

    HDT Bio is a Private company.

  • What is HDT Bio’s current revenue?

    The current revenue for HDT Bio is .

  • How much funding has HDT Bio raised over time?

    HDT Bio has raised $14.5M.

  • Who are HDT Bio’s investors?

    BARDA, Johnson & Johnson Innovation - JLABS, National Institutes of Health, , and are 5 of 7 investors who have invested in HDT Bio.

  • Who are HDT Bio’s competitors?

    Moderna, BioNTech, and Arcturus Therapeutics Holdings are competitors of HDT Bio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process